Search results

641 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter
Quality standards Remove Quality standards filter

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

In development [GID-TA10305] Expected publication date: 31 March 2021

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

In development [GID-TA10334] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

In development [GID-TA10697] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

Type

NICE guideline

Status

In development
Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

Type

NICE guideline

Status

In development
Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

Type

NICE guideline

Status

In development
Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

Type

NICE guideline

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

In development [GID-TA10780] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

In development [GID-TA10416] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

In development [GID-TA10555] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]

In development [GID-TA10712] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]

In development [GID-TA10595] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]

In development [GID-TA10710] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Galcanezumab for preventing cluster headache [ID1212]

In development [GID-TA10425] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Type

Technology appraisal guidance

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

In development [GID-TA10405] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

In development [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development